And as mentioned during our last conference call, we expect cash usage for the full year 2025 of approximately $75,000,000 an increase of approximately $30,000,000 compared with the amount used in 2024, primarily due to investment in clinical test volumes in advance of reimbursement, expansion of our clinical evidence for Next Personal by conducting new studies and additions to our clinical sales team. We expect these investments to help drive NextPersonal revenue growth post reimbursement later this year and into 2026. Now I'd like to turn to guidance. For the 2025, we expect total company revenue in the range of $12,000,000 to $14,000,000 Revenue from pharma tests and services and all other customers in the range of 11,000,000 to $13,000,000 and revenue from population sequencing and enterprise customers of approximately 1,000,000 And for the full year of 2025, we revised our guidance and now expect total company revenue in the range of 70,000,000 to $80,000,000 which is reduced from 80,000,000 to 90,000,000 and this lower range encompasses the timing and variability of biopharma projects and sample receipts and Medicare reimbursement coverage for Next Personal. Revenue from pharma tests and services and all other customers in the range of $52,000,000 to $58,000,000 which is reduced from $62,000,000 to $64,000,000 population sequencing plus enterprise customers in the range of $15,000,000 to 16,000,000 revenue from clinical tests reimbursed in the range of 3,000,000 to $6,000,000 which has narrowed from 3,000,000 to $10,000,000 gross margin in the range of 22% to 24%, and our gross margin guidance for the full year is expected to be lower than the 32% for the full year of 2024 due to the impact of investing in clinical test volume ahead of reimbursement.